GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

jaktinib   Click here for help

GtoPdb Ligand ID: 14393

Synonyms: momelotinib-3,3,5,5-d4 | Zepuping® (China)
Approved drug
jaktinib is an approved drug
Compound class: Synthetic organic
Comment: Jaktinib is a deuterated analogue of momelotinib. It has also been called gecacitinib [2]. The compound behaves as a dual Janus kinase/ACVR1 inhibitor.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 102.11
Molecular weight 414.46
XLogP -0.44
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C1=C(C=CC(=C1)C(=O)NCC#N)C2=NC(=NC=C2)NC3=CC=C(C=C3)N4C([2H])([2H])COCC4([2H])[2H]
Isomeric SMILES [2H]C1(COCC(N1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N)([2H])[2H])[2H]
InChI InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)/i13D2,14D2
InChI Key ZVHNDZWQTBEVRY-RYIWKTDQSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Jaktinib was progressed as a clinical lead for the treatment of myelofibrosis (MF), in particular for ruxolitinib-intolerant MF. First approval was granted by China's NMPA in 2025, to treat disease-related splenomegaly in intermediate or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), and post-essential thrombocythemia myelofibrosis (PET-MF) [1].
Clinical studies are ongoing for other inflammatory (autoimmune) conditions. Trials of Jaktinib in COVID-19 pneumonia have been terminated.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05279001 A Safety and Tolerability Study of Jaktinib Phase 1 Interventional Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT05676242 A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis Phase 3 Interventional Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT05861102 Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) Phase 3 Interventional Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT05861128 Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS) Phase 3 Interventional Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NCT06132243 Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions Phase 1 Interventional Suzhou Zelgen Biopharmaceuticals Co.,Ltd